| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 Oxford University Press
|
|
BRIEF COMMUNICATION |
A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests
For the PEG Group and the ALTS Group
Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), Bethesda, MD (MS, MJK, SW, AH); Howard Hughes Medical Institute, Chevy Chase, MD (MJK); Division of Cancer Prevention, NCI, NIH, DHHS, Bethesda, MD (DS); Proyecto Epidemiológico Guanacaste (PEG), Guanacaste, Costa Rica (RH, ACR, MCB); Departments of Molecular Genetics and Microbiology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center, School of Medicine, Albuquerque, NM (CMW); Albert Einstein College of Medicine, Bronx, NY (RDB)
Correspondence to: Mark Schiffman, MD, MPH, Division of Cancer Epidemiology and Genetics, NCI, 6120 Executive Blvd. Room 7066, EPS MSC 7234, Bethesda, MD 20892-7234 (e-mail: schiffmm{at}mail.nih.gov)
Use of human papillomavirus (HPV) testing in cervical cancer prevention is increasing rapidly. A DNA test for 13 HPV types that can cause cervical cancer is approved in the United States for co-screening with cytology of women 
30 years old and for triage of women of all ages with equivocal cytology. However, most infections with HPV are benign. We evaluated trade-offs between specificity and sensitivity for approximately 40 HPV types in predicting cervical intraepithelial neoplasia 3 and cancer in two prospective studies: a population-based screening study that followed 6196 women aged 30–94 years from Costa Rica for 7 years and a triage study that followed 3363 women aged 18–90 years with equivocal cytology in four U.S. centers for 2 years. For both screening and triage, testing for more than about 10 HPV types decreased specificity more than it increased sensitivity. The minimal increases in sensitivity and in negative predictive value achieved by adding HPV types to DNA tests must be weighed against the projected burden to thousands of women falsely labeled as being at high risk of cervical cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Correspondence about this Article
- Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests
- Silvia Franceschi and Gary M. Clifford
J Natl Cancer Inst 2005 97: 938-939.[Extract] [Full Text] [PDF]
This article has been cited by other articles:
|
|
 |
|
  P. E. Castle, J. T. Cox, J. Jeronimo, D. Solomon, C. M. Wheeler, P. E. Gravitt, and M. Schiffman An Analysis of High-Risk Human Papillomavirus DNA-Negative Cervical Precancers in the ASCUS-LSIL Triage Study (ALTS) Obstet. Gynecol., April 1, 2008; 111(4): 847 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N W J Bulkmans, S Bulk, M S Ottevanger, L Rozendaal, S M Hellenberg, F J van Kemenade, P J F Snijders, A J P Boeke, and C J L M Meijer Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate J. Clin. Pathol., November 1, 2006; 59(11): 1218 - 1220. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. van Hamont, M. A. P. C. van Ham, J. M. J. E. Bakkers, L. F. A. G. Massuger, and W. J. G. Melchers Evaluation of the SPF10-INNO LiPA Human Papillomavirus (HPV) Genotyping Test and the Roche Linear Array HPV Genotyping Test. J. Clin. Microbiol., September 1, 2006; 44(9): 3122 - 3129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Koshiol, J. Schroeder, D. J. Jamieson, S. W. Marshall, A. Duerr, C. M. Heilig, K. V. Shah, R. S. Klein, S. Cu-Uvin, P. Schuman, et al. Smoking and Time to Clearance of Human Papillomavirus Infection in HIV-Seropositive and HIV-Seronegative Women Am. J. Epidemiol., July 15, 2006; 164(2): 176 - 183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. F. Sawaya A 21-Year-Old Woman With Atypical Squamous Cells of Undetermined Significance JAMA, November 2, 2005; 294(17): 2210 - 2218. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Franceschi and G. M. Clifford Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, June 15, 2005; 97(12): 938 - 939. [Full Text] [PDF]
|
|
|
|
|
|
M. Schiffman, P. E. Castle, D. Solomon, M. Stoler, and C. Wheeler RESPONSE: Re: A Study of the Impact of Adding HPV Types to Cervical Cancer Screening and Triage Tests J Natl Cancer Inst, June 15, 2005; 97(12): 939 - 941. [Full Text] [PDF]
|
|